-
Dec 4, 2024 | 
nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 4, 2024 | nature.com | Maximilian Merz |Danai Dima |Nausheen Ahmed |Friedrich Stölzel |Fabian Müller |Aina Oliver-Caldes | +12 more
AbstractDespite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy.
-
Dec 1, 2024 | 
casereports.bmj.com | Ahmad Safdar |Faiz Anwer
DiscussionAmyloidosis involves deposition of toxic protein fibrils that eventually lead to organ dysfunction.1 15 forms of systemic amyloidosis are known, but the most encountered types in clinical practice are amyloid light chain (AL), amyloid A (AA), mutant/hereditary and wild-type amyloid transthyretin (mATTR and wtATTR, respectively).
-
Nov 28, 2024 | 
onlinelibrary.wiley.com | Ludovic Saba |Raymond L. Comenzo |Jack Khouri |Faiz Anwer
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ejh14347-sup-0001-SupinfoS1.docxWord 2007 document , 64.5 KB Data S1. Supporting Information. ejh14347-sup-0002-SupinfoS2.docxWord 2007 document , 19.1 KB Data S2. Supporting Information. References 1 and , “How I Treat AL Amyloidosis,” Blood 139, no. 19 (2022): 2918–2930.
-
Aug 23, 2024 | 
mdpi.com | Barry Paul |Faiz Anwer |Shahzad Raza |Aytaj Mammadzadeh
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Aug 22, 2024 | 
nature.com | Hamlet Gasoyan |Faiz Anwer |Nicholas J. Casacchia |Ming Wang |Michael Halpern
AbstractThis retrospective cohort study used Taussig Cancer Center’s Myeloma Patient Registry to identify adults with multiple myeloma diagnosed between January 2017-December 2021. Electronic health records data captured time from diagnosis to initial prescription fill for oral antimyeloma medications and initiation of facility administered or oral antimyeloma treatment.
-
May 30, 2024 | 
nature.com | Danai Dima |James Davis |Hussein Awada |Faiz Anwer |Shahzad Raza |Zahra Mahmoudjafari | +2 more
AbstractThe presence of extramedullary disease (EMD) has been associated with poor outcomes in patients with relapsed-refractory multiple myeloma (RRMM). Herein, we report the outcomes of RRMM patients who were treated with standard-of-care (SOC) chimeric antigen receptor (CAR) T-cell therapy and had active extraosseous EMD before the infusion. Data were retrospectively collected from patients at three US institutions with the intent to receive SOC CAR T.
-
Nov 17, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Jack Khouri, MD: So, Greg, we seem like a big fan of this. Craig Cole, MD: I didn’t want to tell you. But the patients that I had on [the trial] are what make me a fan. The patients I had when we had to discontinue in November had to stop therapy and remain in very good, or even CRs [complete responses] for months and months. I think the longest one is a patient I still have from November when I discontinued, and she’s still in a CR.
-
Nov 10, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Judy Schreiber, PhD, RN: We’ll go on to the next presentation, which will be Dr [Craig] Cole presenting on the DREAMM-3 study [NCT04162210]. Craig Cole, MD: Thanks, and I was just an investigator on the DREAMM-6 study [NCT03544281]. I want to thank everyone for inviting me, and Dr Weisel for sharing her slides with me. So belantamab mafodotin or Blenrep is a humanized anti-BCMA conjugated antibody.
-
Nov 10, 2023 | 
cancernetwork.com | Andrew Kin |Jeffrey Zonder |Craig Cole |Jay Yang |Charles A. Schiffer |Jack Khouri | +3 more
Transcript:Craig Cole, MD: Faiz, where do you think you’d use a regimen like this? I think this was a French study done a few years ago. How do you think this fits into the landscape these days? Faiz Anwer, MD, FACP: I think this fits in with the more frail or [older] patients. A significant number of patients are not close to a major academic center. There’s a significant number of patients who don’t want to travel so frequently.
